BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 16447748)

  • 1. [Abeta vaccine therapy for Alzheimer's disease].
    Hara H
    Rinsho Shinkeigaku; 2005 Nov; 45(11):867-9. PubMed ID: 16447748
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Vaccination therapy for Alzheimer's disease].
    Tabira T
    Brain Nerve; 2007 Apr; 59(4):375-82. PubMed ID: 17447524
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Novel vaccine therapy for Alzheimer's disease--recent progress and our approach].
    Okura Y; Matsumoto Y
    Brain Nerve; 2008 Aug; 60(8):931-40. PubMed ID: 18717197
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Neuropathology after active Abeta42 immunotherapy: implications for Alzheimer's disease pathogenesis.
    Boche D; Denham N; Holmes C; Nicoll JA
    Acta Neuropathol; 2010 Sep; 120(3):369-84. PubMed ID: 20632020
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Treatment of Alzheimer disease: A beta vaccine].
    Tabira T; Hara H
    Rinsho Shinkeigaku; 2004 Nov; 44(11):778-80. PubMed ID: 15651289
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Consequence of Abeta immunization on the vasculature of human Alzheimer's disease brain.
    Boche D; Zotova E; Weller RO; Love S; Neal JW; Pickering RM; Wilkinson D; Holmes C; Nicoll JA
    Brain; 2008 Dec; 131(Pt 12):3299-310. PubMed ID: 18953056
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduction of amyloid beta-peptide accumulation in Tg2576 transgenic mice by oral vaccination.
    Ishii-Katsuno R; Nakajima A; Katsuno T; Nojima J; Futai E; Sasagawa N; Yoshida T; Watanabe Y; Ishiura S
    Biochem Biophys Res Commun; 2010 Sep; 399(4):593-9. PubMed ID: 20682291
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy as treatment for Alzheimer's disease.
    Hawkes CA; McLaurin J
    Expert Rev Neurother; 2007 Nov; 7(11):1535-48. PubMed ID: 17997702
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Neurobiology. Untangling Alzheimer's by paring plaques bolsters amyloid theory.
    Beckman M
    Science; 2004 Aug; 305(5685):762. PubMed ID: 15297635
    [No Abstract]   [Full Text] [Related]  

  • 10. [Mucosal immunotherapy for alzheimer's disease with viral vectors].
    Hara H; Inoue M; Adachi K; Yonemitsu Y; Hasegawa M; Nabeshima T; Tabira T
    Nihon Shinkei Seishin Yakurigaku Zasshi; 2007 Apr; 27(2):53-6. PubMed ID: 17515110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Nonviral Abeta DNA vaccine therapy against Alzheimer's disease: long-term effects and safety.
    Okura Y; Miyakoshi A; Kohyama K; Park IK; Staufenbiel M; Matsumoto Y
    Proc Natl Acad Sci U S A; 2006 Jun; 103(25):9619-24. PubMed ID: 16769900
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Development of anti-Abeta vaccination as a promising therapy for Alzheimer's disease.
    Okura Y; Matsumoto Y
    Drug News Perspect; 2007; 20(6):379-86. PubMed ID: 17925892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Lessons from the AN 1792 Alzheimer vaccine: lest we forget.
    Robinson SR; Bishop GM; Lee HG; Münch G
    Neurobiol Aging; 2004; 25(5):609-15. PubMed ID: 15172738
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Anti-Abeta: The good, the bad, and the unforeseen.
    Broytman O; Malter JS
    J Neurosci Res; 2004 Feb; 75(3):301-6. PubMed ID: 14743443
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vaccination of Alzheimer's model mice with adenovirus vector containing quadrivalent foldable Abeta(1-15) reduces Abeta burden and behavioral impairment without Abeta-specific T cell response.
    Zou J; Yao Z; Zhang G; Wang H; Xu J; Yew DT; Forster EL
    J Neurol Sci; 2008 Sep; 272(1-2):87-98. PubMed ID: 18571202
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Abeta vaccination and treatment of Alzheimer's disease].
    Takeda K; Hara H
    No To Shinkei; 2005 Oct; 57(10):867-76. PubMed ID: 16277231
    [No Abstract]   [Full Text] [Related]  

  • 17. Amyloid beta peptides with an additional cysteine residue can enhance immunogenicity and reduce the amyloid beta burden in an Alzheimer's disease mouse model.
    Matsuda J; Kaminaka K; Nozaki C
    Biochem Biophys Res Commun; 2009 Apr; 382(1):149-52. PubMed ID: 19265678
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Perspectives in immunotherapy of Alzheimer's disease].
    Rossi G
    Recenti Prog Med; 2003; 94(7-8):305-8. PubMed ID: 12868235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immunotherapy of Alzheimer's disease (AD): from murine models to anti-amyloid beta (Abeta) human monoclonal antibodies.
    Geylis V; Steinitz M
    Autoimmun Rev; 2006 Jan; 5(1):33-9. PubMed ID: 16338209
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence supporting a role for anti-Abeta antibodies in the treatment of Alzheimer's disease.
    Morgan D; Gitter BD
    Neurobiol Aging; 2004; 25(5):605-8. PubMed ID: 15172737
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.